These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22722508)

  • 1. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
    Schoedel KA; Addy C; Chakraborty B; Rosko K; Dunbar S; Maes A; Chen N; Stoch SA; Wagner J; Chodakewitz J; Sellers EM
    J Clin Psychopharmacol; 2012 Aug; 32(4):492-502. PubMed ID: 22722508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
    Addy C; Jumes P; Rosko K; Li S; Li H; Maes A; Johnson-Levonas AO; Chodakewitz J; Stoch SA; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1228-38. PubMed ID: 19783715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests.
    Bosker WM; Kuypers KP; Theunissen EL; Surinx A; Blankespoor RJ; Skopp G; Jeffery WK; Walls HC; van Leeuwen CJ; Ramaekers JG
    Addiction; 2012 Oct; 107(10):1837-44. PubMed ID: 22553980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
    Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, double-blind trial of taranabant for smoking cessation.
    Morrison MF; Ceesay P; Gantz I; Kaufman KD; Lines CR
    Psychopharmacology (Berl); 2010 Apr; 209(3):245-53. PubMed ID: 20191360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
    Aronne LJ; Tonstad S; Moreno M; Gantz I; Erondu N; Suryawanshi S; Molony C; Sieberts S; Nayee J; Meehan AG; Shapiro D; Heymsfield SB; Kaufman KD; Amatruda JM
    Int J Obes (Lond); 2010 May; 34(5):919-35. PubMed ID: 20157323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse liability assessment of atomoxetine in a drug-abusing population.
    Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
    Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
    Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM
    Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
    Fichna J; Sibaev A; Sałaga M; Sobczak M; Storr M
    Neurogastroenterol Motil; 2013 Aug; 25(8):e550-9. PubMed ID: 23692073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
    Addy C; Wright H; Van Laere K; Gantz I; Erondu N; Musser BJ; Lu K; Yuan J; Sanabria-Bohórquez SM; Stoch A; Stevens C; Fong TM; De Lepeleire I; Cilissen C; Cote J; Rosko K; Gendrano IN; Nguyen AM; Gumbiner B; Rothenberg P; de Hoon J; Bormans G; Depré M; Eng WS; Ravussin E; Klein S; Blundell J; Herman GA; Burns HD; Hargreaves RJ; Wagner J; Gottesdiener K; Amatruda JM; Heymsfield SB
    Cell Metab; 2008 Jan; 7(1):68-78. PubMed ID: 18177726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
    Proietto J; Rissanen A; Harp JB; Erondu N; Yu Q; Suryawanshi S; Jones ME; Johnson-Levonas AO; Heymsfield SB; Kaufman KD; Amatruda JM
    Int J Obes (Lond); 2010 Aug; 34(8):1243-54. PubMed ID: 20212496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ketamine as a positive control in human abuse potential studies.
    Shram MJ; Sellers EM; Romach MK
    Drug Alcohol Depend; 2011 Apr; 114(2-3):185-93. PubMed ID: 21109365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.